-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The report "Trends of M&A Transactions in the Healthcare Industry in the First Half of 2022" released by PricewaterhouseCoopers on the 4th at the 2022 Service Trade Fair pointed out that the repeated epidemics in many places in the first half of the year affected the development of investment and financing M&A activities to a certain extent, and the capital market was active.
Compared with the second half of last year, it has declined, but in general, the trend of the medical and health industry is improving, and some sub-sectors have ushered in opportunities and development windows
.
Compared with the second half of last year, it has declined, but in general, the trend of the medical and health industry is improving, and some sub-sectors have ushered in opportunities and development windows
.
The report shows that from 2019 to the first half of 2022, the transaction value of China's medical and health service industry exceeded 200 billion yuan (RMB, the same below), and the number of transactions exceeded 1,000
.
In the first half of 2022, the total amount of transactions in the first half of 2022 decreased compared to the second half of last year.
The total disclosed transaction amount reached 25.
4 billion yuan, the number of transactions was 210, and the average single disclosed transaction amount was about 160 million yuan
.
In terms of large-value transactions, there were 6 transactions of more than 1 billion yuan in total throughout the year, with a transaction size of about 12 billion yuan
.
.
In the first half of 2022, the total amount of transactions in the first half of 2022 decreased compared to the second half of last year.
The total disclosed transaction amount reached 25.
4 billion yuan, the number of transactions was 210, and the average single disclosed transaction amount was about 160 million yuan
.
In terms of large-value transactions, there were 6 transactions of more than 1 billion yuan in total throughout the year, with a transaction size of about 12 billion yuan
.
Qian Liqiang, PwC China and Hong Kong’s Healthcare Industry M&A Leader, said: “In the first half of the year , investment in oncology , rehabilitation, ophthalmology, genetic testing, artificial intelligence and other investment fields was very popular
.
The target companies of the half-year transaction see that service and technology are the core of medical value, and they support the basic logic of value investment in the medical and health industry
.
"
.
The target companies of the half-year transaction see that service and technology are the core of medical value, and they support the basic logic of value investment in the medical and health industry
.
"
Qian Liqiang said that from this extension, enterprises with technical characteristics or technological upgrading and reform and enterprises with high service quality are favored by capital.
In this process, innovation will serve as the main catalyst for the two and further enhance the competition of medical service institutions.
force
.
In this process, innovation will serve as the main catalyst for the two and further enhance the competition of medical service institutions.
force
.
The report shows that in the first half of 2022, hospital and clinic transactions will remain active to a certain extent, with holding-type acquisitions as the mainstay, with the average disclosed transaction amount rising to over RMB 300 million
.
The “large-scale” and “chain-based” mergers and acquisitions of specialized hospitals and chain clinics are still ongoing.
Over 70% of hospital and clinic transactions are specialized medical institutions.
The fields of ophthalmology, stomatology, rehabilitation, assisted reproduction, women and children, and traditional Chinese medicine have attracted capital attention.
.
.
The “large-scale” and “chain-based” mergers and acquisitions of specialized hospitals and chain clinics are still ongoing.
Over 70% of hospital and clinic transactions are specialized medical institutions.
The fields of ophthalmology, stomatology, rehabilitation, assisted reproduction, women and children, and traditional Chinese medicine have attracted capital attention.
.
In addition, in the first half of 2022, the number of transactions of strategic investors exceeded that of financial investors for the first time, accounting for 52%; among these strategic investors, resource integration and capacity expansion were the main transaction drivers
.
Secondly, some cross-border investors have diversified strategic layouts, seeking new business or synergistic business growth points
.
(Finish)
.
Secondly, some cross-border investors have diversified strategic layouts, seeking new business or synergistic business growth points
.
(Finish)
The report "Trends of M&A Transactions in the Healthcare Industry in the First Half of 2022" released by PricewaterhouseCoopers on the 4th at the 2022 Service Trade Fair pointed out that the repeated epidemics in many places in the first half of the year affected the development of investment and financing M&A activities to a certain extent, and the capital market was active.
Compared with the second half of last year, it has declined, but in general, the trend of the medical and health industry is improving, and some sub-sectors have ushered in opportunities and development windows
.
Compared with the second half of last year, it has declined, but in general, the trend of the medical and health industry is improving, and some sub-sectors have ushered in opportunities and development windows
.
The report shows that from 2019 to the first half of 2022, the transaction value of China's medical and health service industry exceeded 200 billion yuan (RMB, the same below), and the number of transactions exceeded 1,000
.
In the first half of 2022, the total amount of transactions in the first half of 2022 decreased compared to the second half of last year.
The total disclosed transaction amount reached 25.
4 billion yuan, the number of transactions was 210, and the average single disclosed transaction amount was about 160 million yuan
.
In terms of large-value transactions, there were 6 transactions of more than 1 billion yuan in total throughout the year, with a transaction size of about 12 billion yuan
.
healthy and healthy.
In the first half of 2022, the total amount of transactions in the first half of 2022 decreased compared to the second half of last year.
The total disclosed transaction amount reached 25.
4 billion yuan, the number of transactions was 210, and the average single disclosed transaction amount was about 160 million yuan
.
In terms of large-value transactions, there were 6 transactions of more than 1 billion yuan in total throughout the year, with a transaction size of about 12 billion yuan
.
Qian Liqiang, PwC China and Hong Kong’s Healthcare Industry M&A Leader, said: “In the first half of the year , investment in oncology , rehabilitation, ophthalmology, genetic testing, artificial intelligence and other investment fields was very popular
.
The target companies of the half-year transaction see that service and technology are the core of medical value, and they support the basic logic of value investment in the medical and health industry
.
"
Oncology enterprise enterprise _.
The target companies of the half-year transaction see that service and technology are the core of medical value, and they support the basic logic of value investment in the medical and health industry
.
"
Qian Liqiang said that from this extension, enterprises with technical characteristics or technological upgrading and reform and enterprises with high service quality are favored by capital.
In this process, innovation will serve as the main catalyst for the two and further enhance the competition of medical service institutions.
force
.
In this process, innovation will serve as the main catalyst for the two and further enhance the competition of medical service institutions.
force
.
The report shows that in the first half of 2022, hospital and clinic transactions will remain active to a certain extent, with holding-type acquisitions as the mainstay, with the average disclosed transaction amount rising to over RMB 300 million
.
The “large-scale” and “chain-based” mergers and acquisitions of specialized hospitals and chain clinics are still ongoing.
Over 70% of hospital and clinic transactions are specialized medical institutions.
The fields of ophthalmology, stomatology, rehabilitation, assisted reproduction, women and children, and traditional Chinese medicine have attracted capital attention.
.
hospital hospital Chinese medicine.
The “large-scale” and “chain-based” mergers and acquisitions of specialized hospitals and chain clinics are still ongoing.
Over 70% of hospital and clinic transactions are specialized medical institutions.
The fields of ophthalmology, stomatology, rehabilitation, assisted reproduction, women and children, and traditional Chinese medicine have attracted capital attention.
.
In addition, in the first half of 2022, the number of transactions of strategic investors exceeded that of financial investors for the first time, accounting for 52%; among these strategic investors, resource integration and capacity expansion were the main transaction drivers
.
Secondly, some cross-border investors have diversified strategic layouts, seeking new business or synergistic business growth points
.
(Finish)
.
Secondly, some cross-border investors have diversified strategic layouts, seeking new business or synergistic business growth points
.
(Finish)
